Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials starting imminently Pipeline of next-generation HDAC6 inhibitors (HDAC6i) also to be advanced in significant cardio-metabolic and neurodegenerative diseases 24 March 2025 – Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology co

On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025 March 24, 2025 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced tha

Tvardi’s previously announced merger with publicly traded Cara Therapeutics is on-track to close in 1H 2025 TTI-101 is currently being evaluated in a Phase 2 study in patients with idiopathic pulmonary fibrosis (REVERTIPF) and a Phase 2 study in patients with hepatocellular carcinoma (REVERTLIVER CANCER) March 19, 2025 -- Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, announced today that results

— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED’s fourth product, and its first approval in hematological malignancies — March 21, 2025 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) with EZH2 mutation who have received at least t

March 21, 2025 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that its innovative drug candidate, CMND-100, has arrived in the United States following successful manufacturing. This marks a key milestone as the Company prepares to initiate its FDA-approved Phase I/IIa clinical trial

March 20, 2025 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the treatment of patients with T cell lymphoma (TCL) is being presented at the 16th Annual T-Cell Lymphoma Forum taking place March 20-22, 2025 in San Diego, CA. “The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong i

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy March 17, 2025 -- EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer man

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of individuals with Types 2 or 3 spinal muscular atrophy (SMA) Late-breaking oral on Elevidys’ Embark two-year data and pooled analysis of Study 101, 102 and Endeavor, demonstrated clinically meaningful and statistically significant improvements across key measures of motor function in boys with Duchenne muscular dystrophy (DMD) Muscle pathology as measured by MRI continued to

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phase 2b ZUPREME-1 trial is designed to evaluate five target doses of petrelintide up to 9 mg over 42 weeks of treatment. Zealand Pharma remains on track to initiate the Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes in the first half of 2025. March 17, 2025 - Zealand Pharma A/S (N

February 2025 witnessed a wave of mergers and acquisitions in the global biopharmaceutical sector. From Pacira BioSciences acquiring GQ Bio Therapeutics GmbH for $32 million to accelerate the development of gene therapy, to Novartis making a $925 million investment to acquire Anthos Therapeutics and its potentially first-in-class drug abelacimab, the industry saw significant strategic moves. Meanwhile, Shen Lian Biomedical’s entry into the human innovative drug sector and Bosai Gene’s acquisitio